This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $37.05, marking a +0.62% move from the previous day.
Bristol Myers' (BMY) Application for UC Drug Validated by EMA
by Zacks Equity Research
Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
Novavax (NVAX) Initiates Phase III Study on COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) initiates phase III study on its coronavirus vaccine, NVX-CoV2373, in the United States and Mexico.
AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
Pfizer (PFE) Lorbrena First-Line sNDA Gets FDA Priority Review
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets priority review from the FDA.
Company News for Dec 29, 2020
by Zacks Equity Research
Companies In The News Are: TSLA, LMT, MYOV, PFE, DASH
4 Transportation Stocks Likely to Keep Flying High in 2021
by Maharathi Basu
Robust advancement in e-commerce and an uptick in freight conditions make transportation stocks attractive investment bets. Evidently, the likes of UPS, Knight-Swift (KNX), Atlas Air (AAWW) and ArcBest (ARCB) should grace one's portfolio.
5 Sector ETFs That Beat the Market in 2020
by Sweta Killa
With historic twists and turns, 2020 has turned out to be a banner year.
3 Restaurant Stocks to Gain Big With the Vaccine Rollout
by Zacks Equity Research
Restaurant industry is likely to benefit from the vaccine rollout. Following the vaccine rollout, dine-in option should become safe and traffic is likely to increase.
5 Stocks That Could Directly Gain From Pfizer's Vaccine Success
by Zacks Equity Research
As vaccine rollout picks up in the United States, companies directly involved in the distribution process stand to benefit, making it wise to keep an eye on names like FedEx (FDX) and Linde (LIN)
The Zacks Analyst Blog Highlights: Apple, JPMorgan, Union Pacific, Pfizer and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, JPMorgan, Union Pacific, Pfizer and Lockheed Martin
Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod
by Zacks Equity Research
The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.
by Zacks Equity Research
Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
Stock Market News for Dec 24, 2020
by Zacks Equity Research
Benchmarks closed mixed on Wednesday after investors¿¿¿ sentiment were overshadowed by President Trump¿¿¿s opposition on fresh stimulus packages passed by the Congress.
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
3 Airlines Stocks to Gain as the Economy Looks to Fully Reopen
by Zacks Equity Research
Rollout of the vaccine along with an expected fiscal stimulus is sure to boost the airlines industry, making it prudent to watch out for names like Mesa Air Group (MESA) and Spirit Airlines (SAVE).
Small-Caps at Record Highs Ahead of Christmas
by Mark Vickery
The small-cap Russell 2000 index has hit another closing record high today -- the 13th time this has occurred this year.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $37.44, moving +1.91% from the previous trading session.
Top Stock Reports for Apple, JPMorgan & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan Chase (JPM), and Union Pacific (UNP).
5 Best-Performing Leveraged ETFs of Fourth Quarter
by Sweta Killa
We highlight some leveraged ETFs that gained more than 85% over the past three months.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
by Zacks Equity Research
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).